ly2979165
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01248052)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
GRM2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](N)C(=O)N[C@@]1(C(=O)O)C[C@@H](Sc2nnc[nH]2)[C@H]2[C@H](C(=O)O)[C@H]21- Mol. weight
- 355.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4303379 ↗
- ChEMBLCHEMBL3544939 ↗
Also known as
- hy-13239
- hy-13239
- ly2979165
- ly2979165
- ly2979165
- ly-2979165
- ly-2979165
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01524237 | Phase 1 | Apr 1, 2012 | Eli Lilly |
| NCT01383967 | Phase 1 | Jul 1, 2011 | Eli Lilly |
| NCT01248052 | Phase 1 | Nov 1, 2010 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 1 | 2010 |
1 organizations
Page 1 / 1